Global Blood Stock Price, News & Analysis

Global Blood Therapeutics (GBT) has awarded $250,000 to five nonprofit organizations focused on improving healthcare access for sickle cell disease (SCD) patients through its 2020 Access to Excellent Care for Sickle Cell Patients (ACCEL) Grant Program. This initiative aims to address healthcare disparities exacerbated by COVID-19. The recipients include organizations from Atrium Health, Augusta University, East Carolina University, OSF Saint Francis Medical Center, and the University of Rochester, all recognized for their innovative proposals aimed at enhancing care for individuals with SCD.

Global Blood Therapeutics (GBT) announced plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Oxbryta (voxelotor) to treat hemolytic anemia in sickle cell disease (SCD) patients aged 12 and older. The submission is targeted for mid-2021. Oxbryta, which is already FDA-approved in the U.S., addresses the root cause of red blood cell sickling. The EMA has previously granted Oxbryta Priority Medicines (PRIME) and orphan medicinal product designations. An Early Access Program in Europe is also planned for early access to the therapy.

Global Blood Therapeutics (GBT) announced plans to expand the use of Oxbryta (voxelotor) for treating sickle cell disease (SCD) in children aged 4 to 11 years, following discussions with the FDA. An NDA submission is expected by mid-2021, including new age-appropriate formulations and data from the ongoing Phase 2a HOPE-KIDS 1 study. Oxbryta works by inhibiting hemoglobin polymerization, a major cause of SCD symptoms. This expansion represents a significant step in treating this inherited condition affecting around 100,000 people in the U.S.

Global Blood Therapeutics (GBT) announced on June 1, 2020, the grant of 34,000 restricted stock units to seven new employees as part of its Amended and Restated 2017 Inducement Equity Plan. These awards are intended to incentivize new hires in compliance with NASDAQ Listing Rule 5635(c)(4). GBT, founded in 2011, focuses on developing treatments for sickle cell disease (SCD), including the FDA-approved Oxbryta (voxelotor) and the pipeline program featuring inclacumab.

Global Blood Therapeutics, Inc. (GBT) will present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020, at 3:50 p.m. ET. The presentation will be available via webcast on GBT's official website. GBT, focused on sickle cell disease treatments, has introduced Oxbryta (voxelotor), the first FDA-approved therapy targeting sickle hemoglobin polymerization. The company is also developing inclacumab, aimed at alleviating pain crises associated with SCD. Archived webcasts will be accessible for a month post-event.

SOUTH SAN FRANCISCO, Calif., May 14, 2020 – Global Blood Therapeutics (GBT) announced four abstracts for the 25th Annual European Hematology Association (EHA) Congress, June 11-14. Key findings from the STOP 2 study reveal that higher hemoglobin levels correlate with lower transcranial Doppler (TCD) flow velocities, reducing stroke risk in children with sickle cell disease (SCD). The data supports the efficacy of Oxbryta^® (voxelotor), the first FDA-approved treatment targeting sickle hemoglobin polymerization, which is also under investigation in the HOPE-KIDS 2 trial.

Global Blood Therapeutics (GBT) announced the grant of 36,500 restricted stock units to seven new employees on May 1, 2020. This action was taken under GBT's Amended and Restated 2017 Inducement Equity Plan, complying with NASDAQ Listing Rule 5635(c)(4). The plan was established to attract and retain talent within the company, focusing on the development of innovative treatments for sickle cell disease (SCD). GBT's flagship treatment, Oxbryta®, is the first FDA-approved therapy targeting the polymerization of sickle hemoglobin, enhancing care for SCD patients.